(base line)
89,121 results
  • Extreme Diagnostic and Therapeutic Heterogeneity Limits Treatment Conclusions in Iliotibial Band Syndrome: A Systematic Review with Level-of-Evidence Stratification. [Review]
    Orthop Res Rev. 2026; 18:629195.Ferrero A, Moro A, … Anzillotti GOR
  • CONCLUSIONS: Despite a broad therapeutic landscape, most treatment modalities cannot yet be recommended over one another. Structured rehabilitation remains the reasonable first-line approach for newly diagnosed ITBS. For refractory ITBS, emerging Level I evidence supports ultrasound-guided PRP as a promising, though not yet independently replicated, minimally invasive option; corticosteroid injection, instrumental therapies and surgery may be considered in selected cases. The absence of standardized diagnostic criteria and extreme methodological heterogeneity across studies - rather than limitations of this review - preclude more definitive conclusions. Future research must prioritize diagnostic standardization and rigorous head-to-head comparative trials, including independent replication of the PRP findings.
  • PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. [Systematic Review]
    Front Oncol. 2026; 16:1884407.Feng J, Qin X, Mo XFO
  • CONCLUSIONS: This network meta-analysis supports biomarker-directed PARP inhibitor-based first-line maintenance in advanced ovarian cancer, with the greatest PFS benefit in BRCA-mutated and HRD-positive populations. No active regimen demonstrated statistically significant superiority within the connected network. The incremental benefit of adding antiangiogenic therapy to PARP inhibition remains uncertain because connected-network evidence for combination strategies was limited and PAOLA-1 could not be incorporated into the primary network. These findings should not be interpreted as evidence against the clinical value of olaparib plus bevacizumab or combination maintenance strategies in general. Treatment selection should integrate molecular status, prior bevacizumab exposure, safety, treatment availability, and patient preference.